Georgirene D. Vladutiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Georgirene D. Vladutiu has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Paul J. Isackson
Department of Pediatrics, School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA
3 shared publicationsRobert L. Wortmann
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
2 shared publicationsAlexandru C. Barboi
Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
1 shared publicationBenjamin H. Natelson
War-Related Illness and Injury Study Center, VA Medical Center, and CFS Cooperative Research Center, UMDNJ-New Jersey Medical School, East Orange, New Jersey
1 shared publicationBeth Cobb
Department of Medicine, Cincinnati Children's Hospital, Cincinnati, OH USA
1 shared publicationJohn B. Harley
Department of Medicine, Cincinnati Children's Hospital, Cincinnati, OH USA
1 shared publication
Latest Publications
- 28 February 2017
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 4 (1) , 77-87
Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy
Background: Statins have well-known benefits in the prevention of cardiovascular disease, however, 7–29% of patients develop muscle side effects and up to 0.5% develop severe symptoms. Mitochondrial dysfunction has been associated with severe statin-
- 28 February 2017
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 4 (1) , 77-87
Histopathologic and Biochemical Evidence for Mitochondrial Disease Among 279 Patients with Severe Statin Myopathy
Background: Statins have well-known benefits in the prevention of cardiovascular disease, however, 7–29% of patients develop muscle side effects and up to 0.5% develop severe symptoms. Mitochondrial dysfunction has been associated with severe statin-
- 1 September 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 104 (1-2) , 167-173
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies
- 1 September 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 104 (1-2) , 167-173
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies
- 31 March 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 102 (3) , 325
Message from the President of the Society for Inherited Metabolic Disorders
- 31 March 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 102 (3) , 325
Message from the President of the Society for Inherited Metabolic Disorders
- 31 January 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 102 (1) , 1-3
SIMD commentary on FDA oversight of laboratory-developed testing
- 31 January 2011
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 102 (1) , 1-3
SIMD commentary on FDA oversight of laboratory-developed testing
- 31 December 2010
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 101 (4) , 305-306
The 2010 Donough O'Brien Presidential Address: The contribution of heterozygosity to disease
- 31 December 2010
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 101 (4) , 305-306
The 2010 Donough O'Brien Presidential Address: The contribution of heterozygosity to disease
- 15 January 2009
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (3) , 304
SLCO1B1Variants and Statin-Induced Myopathy
Investigators in the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group found one single-nucleotide polymorphism (SNP) in the SLCO1B1 gene that was significantly associated with the risk of development of statin-induced myopathy (P=4×10–9) (Aug. 21 issue).1 The study was performed in patients with a history of myocardial infarction taking a high dose (80 mg) of simvastatin.
- 15 January 2009
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 360 (3) , 304
SLCO1B1Variants and Statin-Induced Myopathy
Investigators in the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group found one single-nucleotide polymorphism (SNP) in the SLCO1B1 gene that was significantly associated with the risk of development of statin-induced myopathy (P=4×10–9) (Aug. 21 issue).1 The study was performed in patients with a history of myocardial infarction taking a high dose (80 mg) of simvastatin.
- 1 November 2008
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (6) , 648-655
Genetic predisposition to statin myopathy
Genetic predisposition to statin myopathy is a rapidly expanding area of investigation. This review summarizes the latest information on genetic risk factors associated with statin-induced myopathy. Genetic determinants involved in both pharmacokinetics of statins and metabolic muscle diseases are discussed. Data are provided on the prevalence of statin use in the United States; incidence of associated myopathy; terminology relating to statin myopathy and genetic susceptibility; and common myths surrounding this disorder. Technological advances now make it possible to identify genetic variation in the human genome that reveals disease-causing mutations and single nucleotide polymorphisms associated with disease. More than 30,000 individuals in the United States suffer from severe life-threatening symptoms of statin-induced myopathy that may, in some cases, persist long after the cessation of therapy. Genes of interest include those involved in the pharmacokinetics of the statin response, muscle atrophy, exercise intolerance, pain perception, and mitochondrial energy metabolism. Genetic analysis for variants and disease-causing mutations relevant to statin myopathy will provide predisposition testing for this and other drug-induced disorders. This testing will become an integral part of personalized medicine that will contribute to the safe and informed use of selected drugs and improved compliance.
- 1 November 2008
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (6) , 648-655
Genetic predisposition to statin myopathy
Genetic predisposition to statin myopathy is a rapidly expanding area of investigation. This review summarizes the latest information on genetic risk factors associated with statin-induced myopathy. Genetic determinants involved in both pharmacokinetics of statins and metabolic muscle diseases are discussed. Data are provided on the prevalence of statin use in the United States; incidence of associated myopathy; terminology relating to statin myopathy and genetic susceptibility; and common myths surrounding this disorder. Technological advances now make it possible to identify genetic variation in the human genome that reveals disease-causing mutations and single nucleotide polymorphisms associated with disease. More than 30,000 individuals in the United States suffer from severe life-threatening symptoms of statin-induced myopathy that may, in some cases, persist long after the cessation of therapy. Genes of interest include those involved in the pharmacokinetics of the statin response, muscle atrophy, exercise intolerance, pain perception, and mitochondrial energy metabolism. Genetic analysis for variants and disease-causing mutations relevant to statin myopathy will provide predisposition testing for this and other drug-induced disorders. This testing will become an integral part of personalized medicine that will contribute to the safe and informed use of selected drugs and improved compliance.
- 31 January 2008
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 93 (1) , 1-4
The FDA announces new drug labeling for pharmacogenetic testing: Is personalized medicine becoming a reality?
- 31 January 2008
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 93 (1) , 1-4
The FDA announces new drug labeling for pharmacogenetic testing: Is personalized medicine becoming a reality?
- 2 May 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (2) , 153-162
Genetic risk factors associated with lipid‐lowering drug‐induced myopathies
Lipid‐lowering drugs produce myopathic side effects in up to 7% of treated patients, with severe rhabdomyolysis occurring in as many as 0.5%. Underlying metabolic muscle diseases have not been evaluated extensively. In a cross‐sectional study of 136 patients with drug‐induced myopathies, we report a higher prevalence of underlying metabolic muscle diseases than expected in the general population. Control groups included 116 patients on therapy with no myopathic symptoms, 100 asymptomatic individuals from the general population never exposed to statins, and 106 patients with non–statin‐induced myopathies. Of 110 patients who underwent mutation testing, 10% were heterozygous or homozygous for mutations causing three metabolic myopathies, compared to 3% testing positive among asymptomatic patients on therapy (P = 0.04). The actual number of mutant alleles found in the test group patients was increased fourfold over the control group (P < 0.0001) due to an increased presence of mutation homozygotes. The number of carriers for carnitine palmitoyltransferase II deficiency and for McArdle disease was increased 13‐ and 20‐fold, respectively, over expected general population frequencies. Homozygotes for myoadenylate deaminase deficiency were increased 3.25‐fold with no increase in carrier status. In 52% of muscle biopsies from patients, significant biochemical abnormalities were found in mitochondrial or fatty acid metabolism, with 31% having multiple defects. Variable persistent symptoms occurred in 68% of patients despite cessation of therapy. The effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms may account for myopathic outcomes in certain high‐risk groups. Muscle Nerve, 2006
- 2 May 2006
- Published by Wiley in Muscle & Nerve
- Vol. 34 (2) , 153-162
Genetic risk factors associated with lipid‐lowering drug‐induced myopathies
Lipid‐lowering drugs produce myopathic side effects in up to 7% of treated patients, with severe rhabdomyolysis occurring in as many as 0.5%. Underlying metabolic muscle diseases have not been evaluated extensively. In a cross‐sectional study of 136 patients with drug‐induced myopathies, we report a higher prevalence of underlying metabolic muscle diseases than expected in the general population. Control groups included 116 patients on therapy with no myopathic symptoms, 100 asymptomatic individuals from the general population never exposed to statins, and 106 patients with non–statin‐induced myopathies. Of 110 patients who underwent mutation testing, 10% were heterozygous or homozygous for mutations causing three metabolic myopathies, compared to 3% testing positive among asymptomatic patients on therapy (P = 0.04). The actual number of mutant alleles found in the test group patients was increased fourfold over the control group (P < 0.0001) due to an increased presence of mutation homozygotes. The number of carriers for carnitine palmitoyltransferase II deficiency and for McArdle disease was increased 13‐ and 20‐fold, respectively, over expected general population frequencies. Homozygotes for myoadenylate deaminase deficiency were increased 3.25‐fold with no increase in carrier status. In 52% of muscle biopsies from patients, significant biochemical abnormalities were found in mitochondrial or fatty acid metabolism, with 31% having multiple defects. Variable persistent symptoms occurred in 68% of patients despite cessation of therapy. The effect of statins on energy metabolism combined with a genetic susceptibility to triggering of muscle symptoms may account for myopathic outcomes in certain high‐risk groups. Muscle Nerve, 2006
- 14 May 2004
- Published by Wiley in Muscle & Nerve
- Vol. 30 (1) , 38-43
Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in gulf war veterans
Genes associated with muscle metabolism and physical endurance were evaluated for variants that may contribute to the etiology of medically unexplained severe and chronic fatigue. Subjects included 49 Gulf War veterans and 61 nonveterans with chronic fatigue syndrome (CFS) or idiopathic chronic fatigue (ICF) and 30 veterans and 45 nonveterans who served as healthy controls. Increased risk for CFS/ICF was associated with alterations of the insertion/deletion (I/D) polymorphism in the angiotensin‐converting enzyme gene within the Gulf War veteran sample only. The I allele frequency was decreased in affected versus unaffected veterans (0.15 versus 0.48; odds ratio [OR], 5.08; 95% confidence interval [CI], 1.97–13.35; P < 0.0001). Correspondingly, the II genotype was decreased fourfold in affected veterans (0.08 versus 0.35; OR = 5.87; 95% CI: 1.21–28.36; P = 0.02), and the DD genotype was increased twofold (0.78 versus 0.39; OR, 5.4; 95% CI, 1.6–18.4; P = 0.007). Veterans with the DD genotype were eight times more likely to develop CFS/ICF than were those with the II genotype (OR, 8.30; 95% CI, 1.50–56.09; P = 0.009). Muscle Nerve 30: 38–43, 2004
- 14 May 2004
- Published by Wiley in Muscle & Nerve
- Vol. 30 (1) , 38-43
Association of medically unexplained fatigue with ACE insertion/deletion polymorphism in gulf war veterans
Genes associated with muscle metabolism and physical endurance were evaluated for variants that may contribute to the etiology of medically unexplained severe and chronic fatigue. Subjects included 49 Gulf War veterans and 61 nonveterans with chronic fatigue syndrome (CFS) or idiopathic chronic fatigue (ICF) and 30 veterans and 45 nonveterans who served as healthy controls. Increased risk for CFS/ICF was associated with alterations of the insertion/deletion (I/D) polymorphism in the angiotensin‐converting enzyme gene within the Gulf War veteran sample only. The I allele frequency was decreased in affected versus unaffected veterans (0.15 versus 0.48; odds ratio [OR], 5.08; 95% confidence interval [CI], 1.97–13.35; P < 0.0001). Correspondingly, the II genotype was decreased fourfold in affected veterans (0.08 versus 0.35; OR = 5.87; 95% CI: 1.21–28.36; P = 0.02), and the DD genotype was increased twofold (0.78 versus 0.39; OR, 5.4; 95% CI, 1.6–18.4; P = 0.007). Veterans with the DD genotype were eight times more likely to develop CFS/ICF than were those with the II genotype (OR, 8.30; 95% CI, 1.50–56.09; P = 0.009). Muscle Nerve 30: 38–43, 2004